Instrument Inactif

Communiqués Novartis AG Swiss Exchange

Actions

CH0012005267

Produits pharmaceutiques

Temps réel estimé Cboe Europe 13:07:46 20/08/2026
127,23 ^CHF	0,00%

11:32	Bourse Zurich: petit coup de mou à l'approche de la mi-journée	AW
08:46	Bourse Zurich: bien orientée après les remous du Trésor américain	AW

Communiqués

19/08	Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies	GL
31/07	FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease	GL
21/07	Novartis: Q2 Earnings Snapshot	AQ
21/07	Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed	GL
17/07	Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN	GL
06/07	Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients	GL
02/07	Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)	GL
12/06	Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)	GL
11/06	Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint	GL
08/06	Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026	GL
04/06	Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years	GL
03/06	Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients	GL
01/06	Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML	GL
01/06	Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases	GL
31/05	Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer	GL
26/05	New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength	GL
21/05	Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA	GL
17/05	New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer	GL
11/05	Medicines, Monopolies, And Justice: India’s Fight For Fair Patents	AQ
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
05/05	Novartis : Earnings Document (novartis q1 2026 impact and sustainability update)	PU
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
28/04	Novartis: Q1 Earnings Snapshot	AQ